Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

Thanks for the info. I made some use of it.

Taking Prurisol 200 mg per protocol population and calculating the WORST CASE SCENARIO as follows:
At start
IGA 3: 65 %, IGA 2: 35 %
At finish:
IGA 3: 30 %, IGA 2: 15 %, IGA 1: 40 % and IGA 0 : 15 %

Assume that all IGA 0 subjects at the finish were IGA 2 subjects at the start. That leaves 20 % worth of original IGA 2 subjects to start filling IGA 1 slot. When all original IGA 2 subjects are spent there is still room for 20 % worth of subjects in IGA 1 slot - these must be original IGA 3 subjects.

Conclusion: Based, admittedly, on a small sample at least 30 % (from 20/65) of IGA 3 subjects improved to IGA 0/1. Probably more because this is the absolute worst case scenario. This means that ORAL 200 mg prurisol seems to perform on par with Regeneron's SUBCUTANEOUS (needles, yikes!) dupilumab. Think what 300 mg or 400 mg dose of ORAL prurisol might do.